Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Seismic Therapeutic, Inc.

Seismic Therapeutic Doses First Cohort in Phase 1 Clinical Trial of S‑1117, a Novel Pan‑IgG Protease Therapy for Antibody-Mediated Diseases
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Presents Preclinical Data on S-8484, Its Novel IgE Protease, for Treatment of Allergic Diseases
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Presents New Preclinical Efficacy Data for S-1117 in Prophylactic and Therapeutic Animal Models of Immune Thrombocytopenia (ITP) at 66th ASH Annual Meeting
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Presents New Preclinical Data for S-4321, a Next Generation PD‑1:FcγRIIb-Selective Bifunctional Agonist Antibody for the Treatment of Autoimmune Disease, at ACR Convergence 2024
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic to Participate in Upcoming Investor Conferences
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Presents Data Demonstrating Key Capabilities and Broad Utility of Its Machine Learning-enabled IMPACT Platform to Create Novel Biologic Medicines
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Announces Presentations at Upcoming Scientific and Medical Conferences
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Presents New Preclinical Data on S-1117 in Autoantibody-Mediated Diseases Including Myasthenia Gravis at MGFA Scientific Session at AANEM Annual Meeting
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Announces Participation at Upcoming October Scientific and Medical Conferences
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Appoints Julie Eastland as Independent Board Director
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic to Participate in Upcoming Investor Conferences
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Appoints Brendan St. Amant as General Counsel
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Announces Participation at Multiple Upcoming Scientific Conferences in June 2024
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic to Participate in Upcoming June Investor Conferences
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Presents Preclinical Data on S-1117, its Novel Pan-IgG Protease Addressing Multiple Pathogenic Mechanisms in Autoimmune Disease, at American Academy of Neurology (AAN) 2024
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Announces Participation at Multiple Upcoming Scientific Conferences in April and May 2024
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic to Present Preclinical Data for Novel Immunoglobulin Sculpting Enzyme at AAN Annual Meeting
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Closes $121 Million Series B Financing to Advance Immunology Pipeline Optimized by its Machine Learning Platform
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Announces Presentation of Preclinical Data for Advancing Novel Biologics Drug Programs at the 23rd Annual Meeting of the Federation of Clinical Immunology Societies
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Announces Presentation of Preclinical Data Demonstrating Advances in Novel Biologics Discovery at the PEGS Boston Summit
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Announces Presentation of Preclinical Data for Immunoglobin Sculpting Enzyme and Dual-Cell Bidirectional Antibody Programs at IMMUNOLOGY 2023
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Appoints Melanie Manning as Chief People Officer
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer
From Seismic Therapeutic, Inc.
Via Business Wire
Seismic Therapeutic Launches with $101 Million Series A Financing to Usher in a New Era of Immunology Drug Development Integrating Machine Learning
From Seismic Therapeutic, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.